APC News
End Drug Shortages Act intro’d in Congress
The legislation would expand the sources the FDA may use to declare drug shortages.
November 22, 2024
FDA tirzepatide ‘reconsideration’ period extended
FDA agreed to extend until December 19 a final report on tirzepatide availability to the court.
November 22, 2024
NPR hits the GLP-1 nail on the head
A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right.
November 22, 2024
CALL TO ACTION: Tell FDA to deny drugmakers’ request
Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW!
November 14, 2024
APC to FDA: Just say no to Lilly
This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list.
November 8, 2024
California BOP sends proposed compounding regs to comment period
The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period.
November 8, 2024
Earlier news
November 8, 2024
Hi, Noom!
Welcome to our newest Bronze-level Corporate Patron, Noom!
November 1, 2024
PFMs can get 2.5% credit card processing
A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%.
November 1, 2024
Phoenix compounders, rise!
The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5.
November 1, 2024
APC election results: directors and bylaws
See the results of APC's elections, including four new directors and several changes to our bylaws.
November 1, 2024
You don’t have to miss our GLP-1 briefing
Our briefing, “What's Up with GLP-1 Compounding (And What's Next)?” is now available on demand.
November 1, 2024
PCAC votes against four nominated bulk drug substances
FDA’s Pharmacy Compounding Advisory Committee voted at a meeting Tuesday against adding four substances to the 503A bulks list.
November 1, 2024
Did someone mention glass houses?
Oopsie! The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants.
November 1, 2024
GLP-1s: Keep your patients informed
The P3 October newsletter is perfect for explaining GLP-1s to your patients.
November 1, 2024
Sterile compounders: Check your ingredients
FDA issued a reminder this week to only produce sterile drugs with suitable components.
October 25, 2024
Full of sound and fury, signifying nothing
Novo Nordisk tried to convince the FDA that semaglutide injections are difficult to compound. (Spoiler: They aren't.)
October 18, 2024
Video: APC on Scripps
APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.
October 18, 2024
BREAKING: FDA allows renewed compounding of tirzepatide copies — for now
In a win for continued patient access to compounded versions of Eli Lilly’s Mounjaro and Zepbound, FDA clarified today that pharmacies may continue to prepare copies of those FDA-approved drugs, at least for now.
